Johnson & Johnson delivered robust second-quarter results, surpassing revenue and earnings expectations across all segments and providing an optimistic full-year guidance. The strong performance, coupled with positive management outlook and strategic investments in growth areas, is likely to bolster investor confidence and positively influence the stock in the short term.

[1]